Published in J Rheumatol on October 15, 2006
The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol (2014) 2.82
[International classification of functioning, disability and health and its significance for rheumatology]. Z Rheumatol (2007) 1.53
Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther (2009) 1.42
The impact of a low cost wheelchair on the quality of life of the disabled in the developing world. Med Sci Monit (2012) 1.11
Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS. Ann Rheum Dis (2014) 1.00
Using the International Classification of Functioning, Disability and Health (ICF) to describe children referred to special care or paediatric dental services. PLoS One (2013) 0.92
Challenges comparing functional limitations in rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol (2009) 0.84
Patients with ankylosing spondylitis have increased sick leave--a registry-based case-control study over 7 yrs. Rheumatology (Oxford) (2009) 0.84
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 9 International classification of functioning, disability and health (ICF)]. Z Rheumatol (2014) 0.81
The international classification for functioning, disability and health. A challenge and a need for rheumatology. Clin Rheumatol (2007) 0.79
Clinimetric properties of the ASAS health index in a cohort of Italian patients with axial spondyloarthritis. Health Qual Life Outcomes (2016) 0.79
Death Receptor 3 (TNFRSF25) Increases Mineral Apposition by Osteoblasts and Region Specific New Bone Formation in the Axial Skeleton of Male DBA/1 Mice. J Immunol Res (2015) 0.78
Sociodemographic and disease-related factors are associated with patient-reported anxiety and depression in spondyloarthritis patients in the Swedish SpAScania cohort. Clin Rheumatol (2014) 0.77
Wnt/β-catenin signaling plays a key role in the development of spondyloarthritis. Ann N Y Acad Sci (2015) 0.77
Work productivity is associated with disease activity and functional ability in Italian patients with early axial spondyloarthritis: an observational study from the SPACE cohort. Arthritis Res Ther (2016) 0.75
Social Role Participation Questionnaire for patients with ankylosing spondylitis: translation into Dutch, reliability and construct validity. RMD Open (2016) 0.75
There's more to life than everyday function: the challenge of measuring social role participation in ankylosing spondylitis. Nat Clin Pract Rheumatol (2009) 0.75
[Ankylosing spondylitis. Target treatment criteria]. Z Rheumatol (2009) 0.75
[German translation and cross-cultural adaptation of the ASAS health index : An ICF-based instrument for documentation of functional ability in patients with ankylosing spondylitis]. Z Rheumatol (2016) 0.75
Defining functioning categories in axial Spondyloarthritis: the role of the ASAS Health Index. Rheumatol Int (2017) 0.75
Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain (2005) 11.80
Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis (2010) 10.97
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis (2013) 10.92
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis (2010) 10.03
The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum (2003) 6.68
COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum (2002) 5.57
Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum (2005) 4.12
The International Classification of Functioning, Disability and Health (ICF): a unifying model for the conceptual description of the rehabilitation strategy. J Rehabil Med (2007) 4.06
Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum (2005) 4.06
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis (2007) 4.05
Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum (2008) 4.02
A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum (2012) 4.01
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet (2013) 3.83
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2006) 3.51
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis (2013) 3.43
ICF linking rules: an update based on lessons learned. J Rehabil Med (2005) 3.35
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis (2012) 3.00
Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int (2002) 2.95
Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum (2008) 2.75
Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum (2006) 2.67
Non-invasive measurement of brain viscoelasticity using magnetic resonance elastography. NMR Biomed (2008) 2.66
2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis (2011) 2.61
Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol (2014) 2.52
Linking health-status measurements to the international classification of functioning, disability and health. J Rehabil Med (2002) 2.48
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum (2008) 2.48
The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum (2009) 2.45
Minimal clinically important rehabilitation effects in patients with osteoarthritis of the lower extremities. J Rheumatol (2002) 2.36
Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis (2010) 2.34
International Classification of Functioning, Disability and Health Core Sets for children and youth with cerebral palsy: a consensus meeting. Dev Med Child Neurol (2014) 2.31
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis (2014) 2.24
Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations. Pain (2006) 2.23
The impact of aging and gender on brain viscoelasticity. Neuroimage (2009) 2.15
The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis international Society in response to the US Food and Drug Administration's comments and concerns. Arthritis Rheumatol (2014) 2.14
Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum (2008) 2.14
Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis (2012) 2.10
The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum (2011) 2.10
Noninvasive assessment of the rheological behavior of human organs using multifrequency MR elastography: a study of brain and liver viscoelasticity. Phys Med Biol (2007) 2.08
Development of ICF Core Sets for patients with chronic conditions. J Rehabil Med (2004) 2.08
Creating an interface between the International Classification of Functioning, Disability and Health and physical therapist practice. Phys Ther (2010) 2.07
EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis (2013) 2.05
Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum (2008) 2.04
Fibromyalgia syndrome. J Rheumatol (2007) 2.04
Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery. Rheumatology (Oxford) (2009) 2.00
Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum (2006) 1.99
Validation of the "World Health Organization Disability Assessment Schedule, WHODAS-2" in patients with chronic diseases. Health Qual Life Outcomes (2010) 1.94
Organizing human functioning and rehabilitation research into distinct scientific fields. Part III: Scientific journals. J Rehabil Med (2007) 1.94
MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. Ann Rheum Dis (2011) 1.90
Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis (2013) 1.90
No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study. Ann Rheum Dis (2010) 1.89
Content comparison of health-related quality of life (HRQOL) instruments based on the international classification of functioning, disability and health (ICF). Qual Life Res (2005) 1.88
Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum (2002) 1.86
Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain (2010) 1.84
Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol (2005) 1.84
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med (2015) 1.83
MR-elastography reveals degradation of tissue integrity in multiple sclerosis. Neuroimage (2009) 1.83
Development of the International Classification of Functioning, Disability and Health core sets for hand conditions--results of the World Health Organization International Consensus process. Disabil Rehabil (2011) 1.81
Assessment of liver viscoelasticity using multifrequency MR elastography. Magn Reson Med (2008) 1.80
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum (2013) 1.80
Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum (2003) 1.79
Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis (2010) 1.78
Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum (2009) 1.75
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis (2013) 1.74
Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum (2006) 1.73
Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. Ann Rheum Dis (2011) 1.68
In vivo viscoelastic properties of the brain in normal pressure hydrocephalus. NMR Biomed (2010) 1.67
Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. Arthritis Rheum (2013) 1.67
Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum (2012) 1.66
Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol (2003) 1.65
The impact of differences in EQ-5D and SF-6D utility scores on the acceptability of cost-utility ratios: results across five trial-based cost-utility studies. Value Health (2009) 1.65
Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum (2005) 1.63
Detecting radiological changes in rheumatoid arthritis that are considered important by clinical experts: influence of reading with or without known sequence. J Rheumatol (2002) 1.63
Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. Ann Rheum Dis (2012) 1.62
Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev (2014) 1.60
Consensus on a core set of domains for psoriatic arthritis. J Rheumatol (2007) 1.60
The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study. J Rheumatol (2003) 1.58
Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction? Ann Rheum Dis (2007) 1.58
Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol (2006) 1.57
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med (2015) 1.56
Toward a generalized framework of core measurement areas in clinical trials: a position paper for OMERACT 11. J Rheumatol (2014) 1.56
Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum (2002) 1.55
From inhibition of radiographic progression to maintaining structural integrity: a methodological framework for radiographic progression in rheumatoid arthritis and psoriatic arthritis clinical trials. Ann Rheum Dis (2013) 1.54
Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Ann Intern Med (2009) 1.53